Castle Biosciences CEO Derek J. Maetzold trims stake by 14,496 shares worth $512,445.26

By Public Technologies
  • Castle Biosciences CEO Derek J. Maetzold exercised stock options for 8,580 shares at $2.39 on Sept. 21, 2026.
  • He sold 8,580 shares at a weighted-average $35.33, cutting his direct stake to 21,479 shares.
  • Separate sales of 3,198 shares, 2,718 shares were reported from trusts tied to Maetzold at $35.33.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-063221), on September 23, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk